Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant

G. Weber, U. Gerdemann, I. Caruana, B. Savoldo, N. F. Hensel, K. R. Rabin, E. J. Shpall, J. J. Melenhorst, A. M. Leen, A. J. Barrett, C. M. Bollard

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Adoptive immunotherapy with ex vivo expanded T cells is a promising approach to prevent or treat leukemia. Myeloid leukemias express tumor-associated antigens (TAA) that induce antigen-specific cytotoxic T lymphocyte (CTL) responses in healthy individuals. We explored the feasibility of generating TAA-specific CTLs from stem cell donors of patients with myeloid leukemia to enhance the graft-versus-leukemia effect after stem cell transplantation. CTL lines were manufactured from peripheral blood of 10 healthy donors by stimulation with 15mer peptide libraries of five TAA (proteinase 3 (Pr3), preferentially expressed antigen in melanoma, Wilms tumor gene 1 (WT1), human neutrophil elastase (NE) and melanoma-associated antigen A3) known to be expressed in myeloid leukemias. All CTL lines responded to the mix of five TAA and were multi-specific as assessed by interferon-γ enzyme-linked immunospot. Although donors showed individual patterns of antigen recognition, all responded comparably to the TAAmix. Immunogenic peptides of WT1, Pr3 or NE could be identified by epitope mapping in all donor CTL lines. In vitro experiments showed recognition of partially human leukocyte antigen (HLA)-matched myeloid leukemia blasts. These findings support the development of a single clinical grade multi-tumor antigen-specific T-cell product from the stem cell source, capable of broad reactivity against myeloid malignancies for use in donor-recipient pairs without limitation to a certain HLA-type.

Original languageEnglish
Pages (from-to)1538-1547
Number of pages10
JournalLeukemia
Volume27
Issue number7
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Neoplasm Antigens
Myeloid Leukemia
Cytotoxic T-Lymphocytes
Leukemia
Stem Cells
Tissue Donors
Transplants
Wilms' Tumor Genes
Myeloblastin
Melanoma-Specific Antigens
Leukocyte Elastase
Wilms Tumor
HLA Antigens
Epitope Mapping
T-Lymphocytes
Adoptive Immunotherapy
Antigens
Peptide Library
Stem Cell Transplantation
Interferons

Keywords

  • Cytotoxic T cells
  • Graft-versus-leukemia effect
  • Immunotherapy
  • Myeloid leukemia
  • Stem cell transplantation
  • Tumor-associated antigens

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. / Weber, G.; Gerdemann, U.; Caruana, I.; Savoldo, B.; Hensel, N. F.; Rabin, K. R.; Shpall, E. J.; Melenhorst, J. J.; Leen, A. M.; Barrett, A. J.; Bollard, C. M.

In: Leukemia, Vol. 27, No. 7, 07.2013, p. 1538-1547.

Research output: Contribution to journalArticle

Weber, G, Gerdemann, U, Caruana, I, Savoldo, B, Hensel, NF, Rabin, KR, Shpall, EJ, Melenhorst, JJ, Leen, AM, Barrett, AJ & Bollard, CM 2013, 'Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant', Leukemia, vol. 27, no. 7, pp. 1538-1547. https://doi.org/10.1038/leu.2013.66
Weber, G. ; Gerdemann, U. ; Caruana, I. ; Savoldo, B. ; Hensel, N. F. ; Rabin, K. R. ; Shpall, E. J. ; Melenhorst, J. J. ; Leen, A. M. ; Barrett, A. J. ; Bollard, C. M. / Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. In: Leukemia. 2013 ; Vol. 27, No. 7. pp. 1538-1547.
@article{c86544ed78934b87afa93d1d2a283254,
title = "Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant",
abstract = "Adoptive immunotherapy with ex vivo expanded T cells is a promising approach to prevent or treat leukemia. Myeloid leukemias express tumor-associated antigens (TAA) that induce antigen-specific cytotoxic T lymphocyte (CTL) responses in healthy individuals. We explored the feasibility of generating TAA-specific CTLs from stem cell donors of patients with myeloid leukemia to enhance the graft-versus-leukemia effect after stem cell transplantation. CTL lines were manufactured from peripheral blood of 10 healthy donors by stimulation with 15mer peptide libraries of five TAA (proteinase 3 (Pr3), preferentially expressed antigen in melanoma, Wilms tumor gene 1 (WT1), human neutrophil elastase (NE) and melanoma-associated antigen A3) known to be expressed in myeloid leukemias. All CTL lines responded to the mix of five TAA and were multi-specific as assessed by interferon-γ enzyme-linked immunospot. Although donors showed individual patterns of antigen recognition, all responded comparably to the TAAmix. Immunogenic peptides of WT1, Pr3 or NE could be identified by epitope mapping in all donor CTL lines. In vitro experiments showed recognition of partially human leukocyte antigen (HLA)-matched myeloid leukemia blasts. These findings support the development of a single clinical grade multi-tumor antigen-specific T-cell product from the stem cell source, capable of broad reactivity against myeloid malignancies for use in donor-recipient pairs without limitation to a certain HLA-type.",
keywords = "Cytotoxic T cells, Graft-versus-leukemia effect, Immunotherapy, Myeloid leukemia, Stem cell transplantation, Tumor-associated antigens",
author = "G. Weber and U. Gerdemann and I. Caruana and B. Savoldo and Hensel, {N. F.} and Rabin, {K. R.} and Shpall, {E. J.} and Melenhorst, {J. J.} and Leen, {A. M.} and Barrett, {A. J.} and Bollard, {C. M.}",
year = "2013",
month = "7",
doi = "10.1038/leu.2013.66",
language = "English",
volume = "27",
pages = "1538--1547",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant

AU - Weber, G.

AU - Gerdemann, U.

AU - Caruana, I.

AU - Savoldo, B.

AU - Hensel, N. F.

AU - Rabin, K. R.

AU - Shpall, E. J.

AU - Melenhorst, J. J.

AU - Leen, A. M.

AU - Barrett, A. J.

AU - Bollard, C. M.

PY - 2013/7

Y1 - 2013/7

N2 - Adoptive immunotherapy with ex vivo expanded T cells is a promising approach to prevent or treat leukemia. Myeloid leukemias express tumor-associated antigens (TAA) that induce antigen-specific cytotoxic T lymphocyte (CTL) responses in healthy individuals. We explored the feasibility of generating TAA-specific CTLs from stem cell donors of patients with myeloid leukemia to enhance the graft-versus-leukemia effect after stem cell transplantation. CTL lines were manufactured from peripheral blood of 10 healthy donors by stimulation with 15mer peptide libraries of five TAA (proteinase 3 (Pr3), preferentially expressed antigen in melanoma, Wilms tumor gene 1 (WT1), human neutrophil elastase (NE) and melanoma-associated antigen A3) known to be expressed in myeloid leukemias. All CTL lines responded to the mix of five TAA and were multi-specific as assessed by interferon-γ enzyme-linked immunospot. Although donors showed individual patterns of antigen recognition, all responded comparably to the TAAmix. Immunogenic peptides of WT1, Pr3 or NE could be identified by epitope mapping in all donor CTL lines. In vitro experiments showed recognition of partially human leukocyte antigen (HLA)-matched myeloid leukemia blasts. These findings support the development of a single clinical grade multi-tumor antigen-specific T-cell product from the stem cell source, capable of broad reactivity against myeloid malignancies for use in donor-recipient pairs without limitation to a certain HLA-type.

AB - Adoptive immunotherapy with ex vivo expanded T cells is a promising approach to prevent or treat leukemia. Myeloid leukemias express tumor-associated antigens (TAA) that induce antigen-specific cytotoxic T lymphocyte (CTL) responses in healthy individuals. We explored the feasibility of generating TAA-specific CTLs from stem cell donors of patients with myeloid leukemia to enhance the graft-versus-leukemia effect after stem cell transplantation. CTL lines were manufactured from peripheral blood of 10 healthy donors by stimulation with 15mer peptide libraries of five TAA (proteinase 3 (Pr3), preferentially expressed antigen in melanoma, Wilms tumor gene 1 (WT1), human neutrophil elastase (NE) and melanoma-associated antigen A3) known to be expressed in myeloid leukemias. All CTL lines responded to the mix of five TAA and were multi-specific as assessed by interferon-γ enzyme-linked immunospot. Although donors showed individual patterns of antigen recognition, all responded comparably to the TAAmix. Immunogenic peptides of WT1, Pr3 or NE could be identified by epitope mapping in all donor CTL lines. In vitro experiments showed recognition of partially human leukocyte antigen (HLA)-matched myeloid leukemia blasts. These findings support the development of a single clinical grade multi-tumor antigen-specific T-cell product from the stem cell source, capable of broad reactivity against myeloid malignancies for use in donor-recipient pairs without limitation to a certain HLA-type.

KW - Cytotoxic T cells

KW - Graft-versus-leukemia effect

KW - Immunotherapy

KW - Myeloid leukemia

KW - Stem cell transplantation

KW - Tumor-associated antigens

UR - http://www.scopus.com/inward/record.url?scp=84880259968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880259968&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.66

DO - 10.1038/leu.2013.66

M3 - Article

C2 - 23528871

AN - SCOPUS:84880259968

VL - 27

SP - 1538

EP - 1547

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -